Optimi Health Corp. (OPTH) — Optimi Health completed a GMP production run of its 5mg psilocybin finished drug product, with output destined for commercial treatment-resistant depression prescriptions in Australia plus planned clinical trials in the U.S. and Europe.
All stages, from biomass cultivation and API extraction to encapsulation and packaging, were done in-house under its Health Canada Drug Establishment Licence. The company also updated its bottling configuration for prescriber and patient ease of use, underscoring its vertically integrated manufacturing capacity.
Source: newswire.ca
For the rest of that week's sector news, read our week in review.